Abbot Laboratories  (ABT) shares were downgraded to "market perform" from "outperform" by analysts at BMO Tuesday. 

The firm made the downgrade on valuation, noting that the stock has risen nearly 20% year to date and the company's recent acquisitions of St. Jude Medical and Alere  (ALR) are already represented in the company's stock price.